Dipeptidyl-Peptidase IV Inhibitors
"Dipeptidyl-Peptidase IV Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
| Descriptor ID |
D054873
|
| MeSH Number(s) |
D27.505.519.389.745.335 D27.505.696.422.500
|
| Concept/Terms |
Dipeptidyl-Peptidase IV Inhibitors- Dipeptidyl-Peptidase IV Inhibitors
- Dipeptidyl Peptidase IV Inhibitors
- Inhibitors, Dipeptidyl-Peptidase IV
- Gliptins
- Dipeptidyl-Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl-Peptidase IV Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl-Peptidase IV Inhibitors".
This graph shows the total number of publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in this website by year, and whether "Dipeptidyl-Peptidase IV Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in Profiles.
-
Qaseem A, Obley AJ, Shamliyan T, Hicks LA, Harrod CS, Crandall CJ, Balk EM, Cooney TG, Cross JT, Fitterman N, Lin JS, Maroto M, Miller MC, Shekelle P, Tice JA, Tufte JE, Etxeandia-Ikobaltzeta I, Yost J. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024 May; 177(5):658-666.
-
Lin TY, Kang EY, Shao SC, Lai EC, Wang NK, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS. Association of sodium-glucose cotransporter-2 inhibitors and the risk of retinal vascular occlusion: A real-world retrospective cohort study in Taiwan. Diabetes Metab Res Rev. 2024 Feb; 40(2):e3773.
-
Wai KM, Saroj N, Boucher N, Aggarwal N, Ho AC, Rahimy E. Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression. Ophthalmic Surg Lasers Imaging Retina. 2023 Mar; 54(3):158-165.
-
Pollack PS, Chadwick KD, Smith DM, Billger M, Hirshberg B, Iqbal N, Boulton DW. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin. Cardiovasc Diabetol. 2017 09 13; 16(1):113.
-
Skolnik N, Jaffa FM, Kalyani RR, Johnson E, Shubrook JH. Reducing CV risk in diabetes: An ADA update. J Fam Pract. 2017 May; 66(5):300-308.
-
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28; 130(18):1579-88.